TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability. Risk factors for the development of PML include duration of therapy, prior use of immunosuppressants, and presence of anti-JCV...
Time/action profile ROUTEONSETPEAKDURATION IV unknown unknown unknown Contraindications/Precautions Contraindicated in: Hypersensitivity; Concurrent use of immunosupressants or tumor-necrosis factor inhibitors; History of progressive multifocal leukoencephalopathy (PML); Pediatric: Children <18 yr. Use Cautiousl...
TYSABRIreasestheriskofprogressivemultifocalleukoencephalopathy(PML),an opportunisticviralinfectionofthebrainthatusuallyleadstodeathorseveredisability. RiskfactorsforthedevelopmentofPMLludedurationoftherapy,prioruseof immunosuppressants,andpresenceofanti-JCVantibodies.Thesefactorsshouldbe consideredinthecontextofexpectedbenefit...